Subscribe
e.g. organoids

First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

48 patients with chronic lymphocytic leukemia, B-cell non-Hodgkin lymphoma, or Waldenstrom’s macroglobulinemia, relapsed/refractory after ≥two prior therapies were enrolled in the open-label, single-arm, phase 1 MK-1026-001 study to receive nemtabrutinib 5 mg to 75 mg once-daily in 28-day cycles.
[Cancer Discovery]
Abstract
Published In
NewslettersHematopoiesis News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies

[FDA] The FDA has received reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
Cell Therapy NewsNewsletters
Read more

Modular Chimeric Cytokine Receptors with Leucine Zippers Enhance the Antitumour Activity of CAR T Cells via JAK/STAT Signaling

[Nature Biomedical Engineering] Investigators showed that replacement of the extracellular domains of heterodimeric cytokine receptors in T cells with two leucine zipper motifs provided optimal Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling.
Cell Therapy NewsNewsletters
Read more

CAR+ T Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

[blood] The authors presented the clinicogenomic characterization of a CARTITUDE-4 patient who developed a CAR+ T cell lymphoma post cilta-cel. Diagnostic and staging workup included biopsy analyses and FDG-PET scan.
Cell Therapy NewsNewsletters
Read more
Brought to you by